Puma Biotechnology Inc. (PBYI) announced after the bell Monday that, after meetings with the FDA, it now plans to submit its New Drug Application for the approval of neratinib in mid-2016. The company previously planned to file its NDA for the breast cancer treatment in the first quarter.
from RTT - Before the Bell http://ift.tt/1q1uGTd
via IFTTT
No comments:
Post a Comment